494 related articles for article (PubMed ID: 8880878)
1. Molecular mechanisms of multidrug resistance in cancer chemotherapy.
Nooter K; Stoter G
Pathol Res Pract; 1996 Jul; 192(7):768-80. PubMed ID: 8880878
[TBL] [Abstract][Full Text] [Related]
2. Multidrug resistance: molecular mechanisms and clinical relevance.
Ling V
Cancer Chemother Pharmacol; 1997; 40 Suppl():S3-8. PubMed ID: 9272126
[TBL] [Abstract][Full Text] [Related]
3. Multidrug resistance: clinical relevance in solid tumours and strategies for circumvention.
Kaye SB
Curr Opin Oncol; 1998 Aug; 10 Suppl 1():S15-9. PubMed ID: 9801854
[TBL] [Abstract][Full Text] [Related]
4. A unique human ovarian carcinoma cell line expressing CD34 in association with selection for multidrug resistance.
Minderman H; Vanhoefer U; Toth K; Minderman MD; Rustum YM
Cancer; 1996 Dec; 78(11):2427-36. PubMed ID: 8941015
[TBL] [Abstract][Full Text] [Related]
5. Analysis of the expression of MRP, the gene for a new putative transmembrane drug transporter, in human multidrug resistant lung cancer cell lines.
Zaman GJ; Versantvoort CH; Smit JJ; Eijdems EW; de Haas M; Smith AJ; Broxterman HJ; Mulder NH; de Vries EG; Baas F
Cancer Res; 1993 Apr; 53(8):1747-50. PubMed ID: 8467491
[TBL] [Abstract][Full Text] [Related]
6. Effects of mitomycin C and carboplatin pretreatment on multidrug resistance-associated P-glycoprotein expression and on subsequent suppression of tumor growth by doxorubicin and paclitaxel in human metastatic breast cancer xenografted nude mice.
Ihnat MA; Nervi AM; Anthony SP; Kaltreider RC; Warren AJ; Pesce CA; Davis SA; Lariviere JP; Hamilton JW
Oncol Res; 1999; 11(7):303-10. PubMed ID: 10757444
[TBL] [Abstract][Full Text] [Related]
7. [The causes of treatment ineffectiveness in acute myelogenous leukemia--the role of blast resistance to cytotoxic drugs].
Machaczka M; Rucińska M; Jabłoński M; Skotnicki AB
Przegl Lek; 1998; 55(7-8):407-13. PubMed ID: 10021886
[TBL] [Abstract][Full Text] [Related]
8. Functional multidrug resistance phenotype associated with combined overexpression of Pgp/MDR1 and MRP together with 1-beta-D-arabinofuranosylcytosine sensitivity may predict clinical response in acute myeloid leukemia.
Schuurhuis GJ; Broxterman HJ; Ossenkoppele GJ; Baak JP; Eekman CA; Kuiper CM; Feller N; van Heijningen TH; Klumper E; Pieters R
Clin Cancer Res; 1995 Jan; 1(1):81-93. PubMed ID: 9815890
[TBL] [Abstract][Full Text] [Related]
9. Methods to detect P-glycoprotein-associated multidrug resistance in patients' tumors: consensus recommendations.
Beck WT; Grogan TM; Willman CL; Cordon-Cardo C; Parham DM; Kuttesch JF; Andreeff M; Bates SE; Berard CW; Boyett JM; Brophy NA; Broxterman HJ; Chan HS; Dalton WS; Dietel M; Fojo AT; Gascoyne RD; Head D; Houghton PJ; Srivastava DK; Lehnert M; Leith CP; Paietta E; Pavelic ZP; Weinstein R
Cancer Res; 1996 Jul; 56(13):3010-20. PubMed ID: 8674056
[TBL] [Abstract][Full Text] [Related]
10. Clinical relevance of P-glycoprotein expression in haematological malignancies.
Nooter K; Sonneveld P
Leuk Res; 1994 Apr; 18(4):233-43. PubMed ID: 7909572
[TBL] [Abstract][Full Text] [Related]
11. Expression of the multidrug resistance-associated protein (MRP) gene in human cancers.
Nooter K; Westerman AM; Flens MJ; Zaman GJ; Scheper RJ; van Wingerden KE; Burger H; Oostrum R; Boersma T; Sonneveld P
Clin Cancer Res; 1995 Nov; 1(11):1301-10. PubMed ID: 9815925
[TBL] [Abstract][Full Text] [Related]
12. Differential effects of P-glycoprotein inhibitors on NIH3T3 cells transfected with wild-type (G185) or mutant (V185) multidrug transporters.
Cardarelli CO; Aksentijevich I; Pastan I; Gottesman MM
Cancer Res; 1995 Mar; 55(5):1086-91. PubMed ID: 7866993
[TBL] [Abstract][Full Text] [Related]
13. Overlapping phenotypes of multidrug resistance among panels of human cancer-cell lines.
Izquierdo MA; Shoemaker RH; Flens MJ; Scheffer GL; Wu L; Prather TR; Scheper RJ
Int J Cancer; 1996 Jan; 65(2):230-7. PubMed ID: 8567122
[TBL] [Abstract][Full Text] [Related]
14. Role of multidrug resistance and its pharmacological modulation in acute myeloid leukemia.
List AF
Leukemia; 1996 Jun; 10(6):937-42. PubMed ID: 8667648
[TBL] [Abstract][Full Text] [Related]
15. Multidrug resistance-associated protein: a protein distinct from P-glycoprotein involved in cytotoxic drug expulsion.
Barrand MA; Bagrij T; Neo SY
Gen Pharmacol; 1997 May; 28(5):639-45. PubMed ID: 9184795
[TBL] [Abstract][Full Text] [Related]
16. The role of multidrug resistance and its pharmacological modulation in acute myeloid leukemia.
List AF
Leukemia; 1996 Apr; 10 Suppl 1():S36-8. PubMed ID: 8618469
[TBL] [Abstract][Full Text] [Related]
17. Multidrug resistance (MDR) genes in haematological malignancies.
Nooter K; Sonneveld P
Cytotechnology; 1993; 12(1-3):213-30. PubMed ID: 7765326
[TBL] [Abstract][Full Text] [Related]
18. The prognostic significance of membrane transport-associated multidrug resistance (MDR) proteins in leukemia.
van den Heuvel-Eibrink MM; Sonneveld P; Pieters R
Int J Clin Pharmacol Ther; 2000 Mar; 38(3):94-110. PubMed ID: 10739113
[TBL] [Abstract][Full Text] [Related]
19. Modulation and prevention of multidrug resistance by inhibitors of P-glycoprotein.
Sikic BI; Fisher GA; Lum BL; Halsey J; Beketic-Oreskovic L; Chen G
Cancer Chemother Pharmacol; 1997; 40 Suppl():S13-9. PubMed ID: 9272128
[TBL] [Abstract][Full Text] [Related]
20. A comparison of rhodamine 123 accumulation and efflux in cells with P-glycoprotein-mediated and MRP-associated multidrug resistance phenotypes.
Twentyman PR; Rhodes T; Rayner S
Eur J Cancer; 1994; 30A(9):1360-9. PubMed ID: 7999426
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
